Abstract
Data from this ongoing clinical study indicate telotristat etiprate, a serotonin synthesis inhibitor, is generally safe and well-tolerated. In patients with carcinoid syndrome, telotristat etiprate is producing biochemical and clinical benefits, including improvements in:
o Daily BM frequency
o Flushing episode frequency
o Urinary 5-HIAA levels
o Adequate relief of GI symptoms
As of 2/2012, 15 patients have enrolled and been treated with telotristat etiprate. 12 patients have completed the ascending dose study and 8 of 10 eligible patients have enrolled into the long-term extension.
